IGM Biosciences Inc at Bank of America Biotech SMID Cap Conference Transcript
The program is about to begin. (Operator Instructions) At this time, it is my pleasure to turn the program over to your host, Greg Harrison.
Hi and welcome to the Bank of America SMID Biotech Virtual Conference. I'm Greg Harrison, one of the biotech analysts here at BofA. And today, I'm happy to introduce IGM Biosciences represented by Fred Schwarzer, CEO. Thanks for joining us, everybody. And for those of you out there watching, if you'd like to send any questions, I'm happy to ask them on your behalf.
Questions & Answers
Fred, let's go ahead and just jump right into the Q&A. Maybe just with an intro for people who maybe are less up to speed on IGM, what is differentiating about the IGM class of antibodies as therapeutics relative to traditional IgG antibody treatment?
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |